These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 26535049)
1. Epidemiology and Treatment Guidelines of Negative Symptoms in Schizo-phrenia in Central and Eastern Europe: A Literature Review. Szkultecka-Dębek M; Walczak J; Augustyńska J; Miernik K; Stelmachowski J; Pieniążek I; Obrzut G; Pogroszewska A; Paulić G; Damir M; Antolić S; Tavčar R; Indrikson A; Aadamsoo K; Jankovic S; Pulay AJ; Rimay J; Varga M; Sulkova I; Veržun P Clin Pract Epidemiol Ment Health; 2015; 11():158-65. PubMed ID: 26535049 [TBL] [Abstract][Full Text] [Related]
2. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Haddad PM; Correll CU Ther Adv Psychopharmacol; 2018 Nov; 8(11):303-318. PubMed ID: 30344997 [TBL] [Abstract][Full Text] [Related]
3. Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia. Vidal C; Reese C; Fischer BA; Chiapelli J; Himelhoch S Clin Schizophr Relat Psychoses; 2015; 9(2):88-95. PubMed ID: 23491969 [TBL] [Abstract][Full Text] [Related]
4. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM; Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369 [TBL] [Abstract][Full Text] [Related]
5. Epidemiology and risk factors of schizophrenia. Janoutová J; Janácková P; Serý O; Zeman T; Ambroz P; Kovalová M; Varechová K; Hosák L; Jirík V; Janout V Neuro Endocrinol Lett; 2016; 37(1):1-8. PubMed ID: 26994378 [TBL] [Abstract][Full Text] [Related]
6. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Stip E; Tourjman V Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550 [TBL] [Abstract][Full Text] [Related]
8. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Hartling L; Abou-Setta AM; Dursun S; Mousavi SS; Pasichnyk D; Newton AS Ann Intern Med; 2012 Oct; 157(7):498-511. PubMed ID: 22893011 [TBL] [Abstract][Full Text] [Related]
15. New generation antipsychotics for first episode schizophrenia. Rummel C; Hamann J; Kissling W; Leucht S Cochrane Database Syst Rev; 2003; (4):CD004410. PubMed ID: 14584012 [TBL] [Abstract][Full Text] [Related]
16. [Physical activity in patients with schizophrenia: From neurobiology to clinical benefits]. Tréhout M; Dollfus S Encephale; 2018 Dec; 44(6):538-547. PubMed ID: 29983176 [TBL] [Abstract][Full Text] [Related]
17. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. Harvey RC; James AC; Shields GE CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655 [TBL] [Abstract][Full Text] [Related]
18. The European studies on mortality in schizophrenia. Gondek TM; Królicka A; Piotrowski P; Kiejna A Psychiatr Pol; 2015; 49(6):1139-48. PubMed ID: 26909391 [TBL] [Abstract][Full Text] [Related]
19. [Are schizophrenic patients being told their diagnosis today in France?]. Villani M; Kovess-Masféty V Encephale; 2017 Apr; 43(2):160-169. PubMed ID: 27372353 [TBL] [Abstract][Full Text] [Related]
20. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: A meta-analysis. Bartoli F; Crocamo C; Di Brita C; Esposito G; Tabacchi TI; Verrengia E; Clerici M; Carrà G J Psychiatr Res; 2019 Jan; 108():24-33. PubMed ID: 30447508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]